Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Pilot Study on Gene Expression Profiling of the Endometrial Tissue in Patients Undergoing Assisted Reproductive Technology (ART: IVF/ICSI) With GONAL-f.

Trial Profile

Open Label Pilot Study on Gene Expression Profiling of the Endometrial Tissue in Patients Undergoing Assisted Reproductive Technology (ART: IVF/ICSI) With GONAL-f.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Choriogonadotropin alfa (Primary) ; Follitropin alfa (Primary) ; LHRH receptor agonists; LHRH receptor antagonists
  • Indications Female infertility
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms EXPRESS
  • Sponsors Merck KGaA

Most Recent Events

  • 03 Jul 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
  • 03 Jul 2012 Planned end date changed from 25 Sep 2009 to 1 Aug 2010 as reported by ClinicalTrials.gov.
  • 17 Mar 2012 Planned patient number is 60 according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top